CA3236854A1 - Protein tyrosine phosphatase inhibitors and methods of use thereof - Google Patents

Protein tyrosine phosphatase inhibitors and methods of use thereof Download PDF

Info

Publication number
CA3236854A1
CA3236854A1 CA3236854A CA3236854A CA3236854A1 CA 3236854 A1 CA3236854 A1 CA 3236854A1 CA 3236854 A CA3236854 A CA 3236854A CA 3236854 A CA3236854 A CA 3236854A CA 3236854 A1 CA3236854 A1 CA 3236854A1
Authority
CA
Canada
Prior art keywords
dihydro
hydroxy
fluoro
mmol
trione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3236854A
Other languages
English (en)
French (fr)
Inventor
Andrew Bogdan
Elliot P. Farney
Jennifer M. Frost
Philip R. Kym
Zhaoming Xiong
Naomi Anne Barton
Claire Anne Marie CARIOU-MUMFORD
Christopher Patrick Mcmahon
Giuseppe Nano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Calico Life Sciences LLC
Original Assignee
AbbVie Inc
Calico Life Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc, Calico Life Sciences LLC filed Critical AbbVie Inc
Publication of CA3236854A1 publication Critical patent/CA3236854A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3236854A 2021-11-11 2022-11-10 Protein tyrosine phosphatase inhibitors and methods of use thereof Pending CA3236854A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163278339P 2021-11-11 2021-11-11
US63/278,339 2021-11-11
PCT/US2022/049584 WO2023086498A1 (en) 2021-11-11 2022-11-10 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3236854A1 true CA3236854A1 (en) 2023-05-19

Family

ID=84689141

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3236854A Pending CA3236854A1 (en) 2021-11-11 2022-11-10 Protein tyrosine phosphatase inhibitors and methods of use thereof

Country Status (8)

Country Link
US (1) US20250019374A1 (cg-RX-API-DMAC7.html)
EP (1) EP4430038A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543452A (cg-RX-API-DMAC7.html)
CN (1) CN118525016A (cg-RX-API-DMAC7.html)
AU (1) AU2022387106A1 (cg-RX-API-DMAC7.html)
CA (1) CA3236854A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005658A (cg-RX-API-DMAC7.html)
WO (1) WO2023086498A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
CN121487923A (zh) * 2023-07-28 2026-02-06 杭州中美华东制药有限公司 具有ptpn2抑制作用的化合物及其用途
WO2025242216A1 (zh) * 2024-05-24 2025-11-27 杭州百新生物医药科技有限公司 吲哚啉类化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
TWI888352B (zh) * 2018-06-21 2025-07-01 美商嘉來克生命科學有限責任公司 蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法
KR102983496B1 (ko) * 2019-03-14 2026-06-29 칼리코 라이프 사이언시스 엘엘씨 단백질 티로신 포스파타제 억제제 및 이의 사용 방법
MX2022007441A (es) * 2019-12-18 2022-09-02 Calico Life Sciences Llc Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.

Also Published As

Publication number Publication date
CN118525016A (zh) 2024-08-20
AU2022387106A1 (en) 2024-05-23
US20250019374A1 (en) 2025-01-16
EP4430038A1 (en) 2024-09-18
WO2023086498A1 (en) 2023-05-19
JP2024543452A (ja) 2024-11-21
MX2024005658A (es) 2024-08-06

Similar Documents

Publication Publication Date Title
EP3555096B1 (en) Imidazopyrrolopyridine as inhibitors of the jak family of kinases
EP3686196B1 (en) Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor
US20180022752A1 (en) Fused-ring compounds, pharmaceutical composition and uses thereof
AU2022387106A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
KR20230142745A (ko) Cdk2 억제제 및 그의 사용 방법
KR20200010440A (ko) 야누스 키나아제 저해제의 글루쿠로니드 프로드러그
JP2009197010A (ja) Pparアゴニスト活性を有する誘導体
AU2020405536B2 (en) Benzimidazole derivatives
WO2021161105A1 (en) P2x3 modulators
WO2023184327A1 (en) Kinase inhibitors, preparation methods and uses thereof
EP2834234A1 (en) Fused cyclopentyl antagonists of ccr2
EP3400226A1 (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
EP3707136B1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
TW202448866A (zh) 治療性化合物
CA3258870A1 (en) Substituted pyridinone compounds used as CBL-B inhibitors
CA3082276C (en) Heterocyclic compounds and their application in medicine
CA3236853A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
TWI652265B (zh) 氮雜吲哚衍生物
JP3999861B2 (ja) 新規ピリダジン誘導体及びこれを有効成分とする医薬
OA22157A (en) Substituted pyridinone compounds as CBL-B inhibitors.
CN122003422A (zh) 杂环pad4抑制剂
HK40055239A (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
NZ626745A (en) Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof
NZ626745B2 (en) Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof
HK40032870A (en) Spirocycle compounds and methods of making and using same

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251031

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251031

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20260623

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260629

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260706

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260729